According to Wise owl report, if cbz has a 50% chance of success...

According to Wise owl report, if cbz has a 50% chance of success and gets 4% of the market they should be trading around $1.70 mark.
This is very conservative going on both previous trials aswell at what % of the market they will get.

There are 3 main companies at roughly the same stage as CBZ ie pre phase 2 results, market caps range from 200 mill to 400 mill, our market cap is less than 100 mill.

2 weeks ago in another sign of just how hot antibodies have become in the rheumatoid arthritis arena, Abbott is plunking down $85 million up front and promising up to $385 million more to partner with Germany's Biotest on a mid-stage mAb with strong potential to emerge as a therapeutic for RA and psoriasis

CBZ's previous trials have shown less side effects than any other major drug on the market(considering that the side effects of these other players are illnesses such as cancers) and that patients who recorded a 20% or more improvement was greater for CBZ than any other drug on the market.

Humira which has currently the best RA drug in the market (for patients recording a 20% or more improvement) has revenues of US4.5 Billion in 2008, Enbrel is next with a US 6.5 billion annual revenue and Remicade is next with US 6.2 bill in annual revenue.Please note that CBIO's drug is also cheapest of the 4 to manufacture.

If we compare CBZ to its peers that are at the same stage it should be trading between $1.40 and $2.80.
If we are successful and trade with the top 4 biggest which we should with Novo behind us then we should be looking at revenues of around 5-6 bill per annum.

What price is fair for Novo to get control of xtoll?